Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?
- 20 December 2022
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (36) , 4173-4177
Abstract
Prostate cancer patients with CVD can safely and effectively be treated with either LHRH agonists or antagonistsKeywords
This publication has 32 references indexed in Scilit:
- A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancerMedicine, 2016
- Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE−/− miceScientific Reports, 2016
- Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysisEuropean Urology, 2015
- GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse modelUrologic Oncology: Seminars and Original Investigations, 2014
- Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an AntagonistEuropean Urology, 2014
- Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate CancerJAMA, 2011
- Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate CancerJournal of Urology, 2010
- The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancerBJU International, 2008
- Androgen Deprivation Therapy for Localized Prostate Cancer and the Risk of Cardiovascular MortalityJNCI: Journal of the National Cancer Institute, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006